What is the primary driver of the decrease in net earnings compared to the prior year's quarter?

The decrease in net earnings was primarily driven by an increase in the cost of products sold due to a change in product mix, higher marketing, selling, and administrative expenses, and increased advertising and promotion spending. These factors outweighed the slight increase in net sales and a gain from a vitamins litigation settlement.

How is Bristol-Myers Squibb managing its relationship with major pharmaceutical wholesalers like Cardinal and McKesson?

The company is applying a consignment model for certain sales to Cardinal Health and McKesson. This means revenue is recognized not upon shipment, but when the product is sold through to the wholesaler's customers. This has resulted in significant deferred revenue ($174 million) and consignment inventory balances on the balance sheet, which are expected to be substantially cleared by the end of 2003.

What is the status of the major litigation matters mentioned in the filing?

The company has reached agreements in principle to settle substantially all antitrust litigation surrounding TAXOL® for an expected $135 million and BUSPAR® for an expected $535 million. These amounts have been accrued in prior periods. While agreements are in place, finalization, court approval, and opt-out periods are pending. The company is also cooperating with ongoing investigations by the SEC and the U.S. Attorney's Office related to wholesaler inventory and accounting issues.

How are key products performing, and what are the main challenges?

Key products like PRAVACHOL and AVAPRO showed strong sales growth. However, PLAVIX* sales declined due to wholesaler buying patterns anticipating a price increase and inventory workdown. GLUCOPHAGE* franchise sales were impacted by generic competition for GLUCOPHAGE*IR, although GLUCOVANCE* and GLUCOPHAGE*XR showed growth. TAXOL® sales significantly declined in the U.S. due to generic competition.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY2003

Summary

Bristol-Myers Squibb Company (BMY) reported first quarter 2003 results with a slight increase in net sales to $4.711 billion, up 1% from the prior year. However, net earnings experienced a decline, falling 10% to $761 million, or $0.39 per diluted share, compared to $856 million, or $0.44 per diluted share, in the first quarter of 2002. This decrease in profitability was attributed to higher cost of products sold, increased marketing and selling expenses, and a shift in product mix towards lower-margin products, partially offset by a gain from a vitamins litigation settlement. The company continued to face challenges with generic competition impacting key drugs like GLUCOPHAGE*IR and TAXOL*. While international sales showed robust growth, domestic pharmaceutical sales saw a decline. The company is actively managing its wholesaler inventory levels, which impacted reported sales figures. Significant legal matters, including ongoing litigation related to TAXOL® and BUSPAR®, continue to be a focus, with substantial settlement accruals made in prior periods.

Key Highlights

1Net sales increased slightly by 1% to $4.711 billion, driven by international growth and favorable foreign exchange rates, partially offset by a 6% decrease in domestic sales.
2Net earnings decreased by 10% to $761 million ($0.39 per diluted share) from $856 million ($0.44 per diluted share) in the prior year's quarter.
3Pharmaceutical segment sales grew 2%, but earnings before minority interest and income taxes declined due to generic competition (GLUCOPHAGE*IR, TAXOL®) and increased expenses.
4Significant legal settlements are being finalized for TAXOL® ($135 million accrued in Q3 2002) and BUSPAR® ($535 million accrued over prior periods), indicating substantial contingent liabilities.
5The company is implementing a consignment model for certain sales to major U.S. wholesalers (Cardinal and McKesson), impacting revenue recognition and deferred revenue balances ($174 million at quarter-end).
6Research and development expenditures decreased by 5% to $476 million, reflecting timing of clinical trials and cost-saving measures.
7The company is actively managing wholesaler inventory levels, with substantial completion of an orderly workdown expected by the end of 2003.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2003

Summary

Key Highlights

Frequently Asked Questions